The story of Sildenafil presents a complex case for investors in the medicinal sector. While initially a phenomenal success, generating huge profits, the patent end and the subsequent flood of off-brand alternatives https://porn812615.luwebs.com/42711450/the-little-copyright-and-the-pharmaceutical-industry-a-risky-bet